Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Buy rating on NeoGenomics (NASDAQ:NEO) and maintains an $18 price target.
May 01, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Buy rating on NeoGenomics with an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by a Benchmark analyst could positively influence investor sentiment towards NeoGenomics, potentially driving short-term price movement upwards.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100